Jin10 reported on October 29 that Yipin Hong announced the latest clinical results of its innovative gout drug deuterated benzbromarone (AR882) for the treatment of gout stones at ACR2025 (American College of Rheumatology Annual Meeting). The clinical conclusion shows that for patients with newly diagnosed and refractory gout stones, monotherapy with deuterated benzbromarone or combined therapy with allopurinol can effectively drop sUA, reduce the burden of urate crystals, and achieve a high complete dissolution rate of target gout stones. Monotherapy or combination therapy with deuterated benzbromarone can provide a more effective treatment option for chronic gout stone patients who have poor efficacy with existing treatment regimens.